IPILIMUMAB PLUS LENALIDOMIDE FOR TREATMENT OF RELAPSED DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) IN PATIENTS (PTS) WITH LYMPHOID MALIGNANCIES
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.124_2630
Abstract: vation of CD56+ NKC as opposed to NR (Figure 1). NKC cytotoxicity through the expression of Granzyme B was seen in R vs NR. Flow quantitation of circulating CD4+ CD25+ T cells (Tregs) shows a… read more here.
Keywords: plus lenalidomide; ipilimumab plus; relapsed disease; lenalidomide treatment ... See more keywords
Lenalidomide for the treatment of mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2018.1561865
Abstract: ABSTRACT Introduction: Although a variety of therapeutic schemes for Mantle Cell Lymphoma (MCL) have been attempted, the clinical outcome of patients continues to be unsatisfactory especially among patients with a very high-risk profile and in… read more here.
Keywords: relapsed refractory; treatment mantle; treatment; lenalidomide treatment ... See more keywords
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "OncoImmunology"
DOI: 10.1080/2162402x.2017.1316438
Abstract: ABSTRACT Recent studies suggest that CLL is an immunogenic disease, which might be effectively targeted by antigen-specific T-cell-based immunotherapy. However, CLL is associated with a profound immune defect, which might represent a critical limitation for… read more here.
Keywords: cll; cell based; lenalidomide treatment; based immunotherapy ... See more keywords